Forward Pharma Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Forward Pharma's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Forward Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -1 | 4 | 0 |
| 31 Mar 22 | 0 | -1 | 4 | 0 |
| 31 Dec 21 | 0 | -2 | 4 | 0 |
| 30 Sep 21 | 0 | -4 | 3 | 0 |
| 30 Jun 21 | 0 | -5 | 3 | 0 |
| 31 Mar 21 | 0 | -6 | 3 | 0 |
| 31 Dec 20 | 0 | -6 | 3 | 0 |
| 30 Sep 20 | 0 | -5 | 3 | 0 |
| 30 Jun 20 | 0 | -4 | 3 | 1 |
| 31 Mar 20 | 0 | -4 | 4 | 1 |
| 31 Dec 19 | 0 | -4 | 4 | 1 |
| 30 Sep 19 | 0 | -5 | 5 | 1 |
| 30 Jun 19 | 0 | -6 | 6 | 2 |
| 31 Mar 19 | 0 | -8 | 7 | 2 |
| 31 Dec 18 | 0 | -9 | 9 | 3 |
| 30 Sep 18 | 0 | -19 | 12 | 5 |
| 30 Jun 18 | 0 | -29 | 13 | 15 |
| 31 Mar 18 | 0 | 444 | 15 | 18 |
| 31 Dec 17 | 0 | 917 | 19 | 13 |
| 30 Sep 17 | 0 | 939 | 19 | 20 |
| 30 Jun 17 | 0 | 940 | 18 | 25 |
| 31 Mar 17 | 0 | 454 | 16 | 35 |
| 31 Dec 16 | 0 | -33 | 14 | 41 |
| 30 Sep 16 | 0 | -53 | 13 | 39 |
| 30 Jun 16 | 0 | -57 | 14 | 43 |
| 31 Mar 16 | 0 | -60 | 15 | 39 |
| 31 Dec 15 | 0 | -37 | 16 | 34 |
| 30 Sep 15 | 0 | -72 | 16 | 29 |
| 30 Jun 15 | 0 | -65 | 14 | 20 |
| 31 Mar 15 | 0 | -50 | 11 | 13 |
| 31 Dec 14 | 0 | -62 | 9 | 11 |
| 30 Sep 14 | 0 | -28 | 6 | 8 |
| 30 Jun 14 | 0 | -23 | 3 | 10 |
| 31 Mar 14 | 0 | -21 | 3 | 9 |
Quality Earnings: Insufficient data to determine if FWPA.Y has high quality earnings.
Growing Profit Margin: Insufficient data to determine if FWPA.Y's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if FWPA.Y's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare FWPA.Y's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if FWPA.Y's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: FWPA.Y has a negative Return on Equity (0%), as it is currently unprofitable.